biosimilars
A collaborative care approach to biosimilars
Video 1: Michelle Leech: Bolstering patient confidence through collaborative care Professor Michelle Leech, Head of the Rheumatoid Arthritis Clinic at Monash Health, Victoria, explains the importance of bolstering patient confidence through …
Gerald Tracey: Collaborative care and supporting the transition to biosimilars
Rheumatologist, Dr Gerald Tracey explains the opportunities biosimilars present for prescribing physicians, particularly given the government supported streamlined process. Gerald highlights the advantages of collaborative care between the prescriber and …
Trent Twomey: The role of pharmacists and physicians in supporting a patient-centric narrative
Trent Twomey, the National President of the Pharmacy Guild of Australia highlights the shifting power dynamic from physicians to patients in determining what medicines they are prescribed. Collaborative care is …
Andrew Oster: The power of collaborative care in transitioning to biosimilars
Professor Andrew Oster, Consultant Rheumatologist at the Cabrini Medical Centre in Malvern, Victoria, explains the opportunities biosimilars bring, allowing patients to switch medications. Given the interchangeability of biosimilars, he emphasises …
Eric Chan: Cultivating a relationship of trust between pharmacist and physician
Head of Pharmacy at Blooms The Chemist, Eric Chan emphasises the importance of collaborative care in cultivating a relationship of trust and transparency between a pharmacist and physician. He outlines …
Michelle Leech: Bolstering patient confidence through collaborative care
Professor Michelle Leech, Head of the Rheumatoid Arthritis Clinic at Monash Health, Victoria, explains the importance of bolstering patient confidence through collaborative care. Displaying this combined physician and pharmacist approach …
George Tambassis: Empowering and educating pharmacists on biosimilars
George Tambassis, Pharmacist, ex-National Guild President, and chair of the Australian Biosimilar Academy Advisory Board outlines the importance of pharmacist involvement in understanding biosimilars. Given the government supported Community Pharmacy …
Biosimilars—here to stay (Updated July 2021)
Up until now, most biosimilars have been in the domain of public and private hospitals, however the release shortly of biosimilar adalimumab, which is currently a self-administered subcutaneous injection, means …
Clinical tips: Biologicals and biosimilars
Biosimilars and the pharmacist’s role in their supply remains controversial, writes Carlene McMaugh Biological pharmaceutical products have been a part of the landscape of therapeutics for a number of years …
New biosimilars listed on the PBS
Here’s what you need to know While there are not many biosimilars available yet in Australia, several have been added to the ARTG and PBS this year. Biosimilar medicines are …
A wake-up call
A recent survey found that pharmacist comfort with supplying biosimilars is going backward, so what can be done to turn this around? In 2018, 361 community pharmacists were surveyed across …
Biologics switching is in pharmacists’ scope
Pharmacists’ authority to use their expertise to substitute one medicine for another should also apply to biological medicines, says FIP The International Pharmaceutical Federation has published a revised Statement of …